haloperidol and Chronic Motor and Vocal Tic Disorder studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

Excerpt	Relevance	Reference
"To evaluate the therapeutic effectiveness and safety of clonidine adhesive patch in treating Tourette syndrome (TS)."	9.22	Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch. ( Jiao, F; Wang, J; Zhang, X, 2016)
"Nine patients with trichotillomania were treated with haloperidol."	9.09	The potential role of haloperidol in the treatment of trichotillomania. ( Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M, 1999)
"Pimozide, a dopamine receptor antagonist, dopamine uptake inhibitor and L-type calcium channel blocker, is used in children suffering from Tourette syndrome (TS), but its effect on frequently comorbid attention deficit hyperactivity disorder (ADHD) is unknown."	9.07	Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. ( Rock, CM; Sallee, FR; Sethuraman, G, 1994)
"The results of this clinical study of 31 patients with Tourette syndrome suggest that pimozide is more effective and induces fewer side effects than haloperidol in some patients."	9.05	Treatment of Gilles de la Tourette syndrome with pimozide. ( Eisenkraft, GJ; Shapiro, AK; Shapiro, E, 1983)
"To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome."	8.85	Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009)
"Levetiracetam, an anti-epileptic agent that enhances GABAergic neurotransmission, is one of the newest alternative treatments of Tourette syndrome (TS)."	7.74	Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome. ( Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN; Papageorgiou, C; Soldatos, CR, 2008)
"Erythrocyte and plasma choline parameters were compared in children (n = 63), aged 6-18 years, suffering from Tourette Syndrome (TS), their parents (n = 57), their unaffected siblings (n = 38), and an adult control group (n = 57)."	7.68	Controlled study of erythrocyte choline in Tourette syndrome. ( Hanin, I; Kopp, U; Sallee, FR, 1992)
"A ten year old boy developed features of Tourette syndrome while taking haloperidol for behaviour problems."	7.68	A case of Tourette syndrome developing during haloperidol treatment. ( Karagianis, JL; Nagpurkar, R, 1990)
"The relationship between a medication course with haloperidol (Haldol) and family history for any type of tics was examined in a survey of 196 Tourette syndrome patients."	7.67	Treating Tourette syndrome with haloperidol: predictors of success. ( Konkol, RJ; Schwabe, MJ, 1989)
"A 23-year-old male with a history of severe Tourette syndrome refractory to treatment with oral haloperidol is reported."	7.67	Treatment of refractory Tourette syndrome with haloperidol decanoate. ( Clarke, DJ; Ford, R, 1988)
"The development of school phobia has been reported in some patients with Tourette syndrome treated with haloperidol."	7.67	Tourette syndrome, pimozide, and school phobia: the neuroleptic separation anxiety syndrome. ( Linet, LS, 1985)
"Three patients suffering from Gilles de la Tourette Syndrome were initially treated with haloperidol."	7.65	Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. ( Erickson, HM; Goggin, JE; Messiha, FS, 1977)
"Nicotine was found to markedly potentiate haloperidol-induced hypokinesia in rats."	5.28	Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. ( Blythe, MM; Fogelson, HM; Klykylo, WM; Manderscheid, PZ; McConville, BJ; Norman, AB; Parker, KW; Sanberg, PR, 1989)
"To evaluate the therapeutic effectiveness and safety of clonidine adhesive patch in treating Tourette syndrome (TS)."	5.22	Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch. ( Jiao, F; Wang, J; Zhang, X, 2016)
"Nine patients with trichotillomania were treated with haloperidol."	5.09	The potential role of haloperidol in the treatment of trichotillomania. ( Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M, 1999)
"Pimozide, a dopamine receptor antagonist, dopamine uptake inhibitor and L-type calcium channel blocker, is used in children suffering from Tourette syndrome (TS), but its effect on frequently comorbid attention deficit hyperactivity disorder (ADHD) is unknown."	5.07	Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. ( Rock, CM; Sallee, FR; Sethuraman, G, 1994)
"We describe a long-term follow-up study (1-15 years) of 33 patients with Tourette syndrome who were treated with pimozide (2-18 mg), haloperidol (2-15 mg), or no drugs."	5.06	Tourette syndrome: a follow-up study. ( Lang, A; Moldofsky, H; Musisi, S; Sandor, P, 1990)
"The results of this clinical study of 31 patients with Tourette syndrome suggest that pimozide is more effective and induces fewer side effects than haloperidol in some patients."	5.05	Treatment of Gilles de la Tourette syndrome with pimozide. ( Eisenkraft, GJ; Shapiro, AK; Shapiro, E, 1983)
"The neurological disorder Gilles de la Tourette syndrome is most often treated with the receptor blocker haloperidol, which also produces multiple side-effects, including the risk for tardive dyskinesia."	5.05	Treatment approaches in Gilles de la Tourette syndrome. ( Ang, L; Borison, RL; Davis, JM; Diamond, BI; Hamilton, WJ, 1983)
"To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome."	4.85	Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009)
" In the Gilles-de-la-Tourette syndrome nicotine reduces the severity and frequency of the tics given in combination with haloperidol."	4.79	[Nicotine in neuropsychiatric movement disorders]. ( Erdmann, R, 1996)
"Levetiracetam, an anti-epileptic agent that enhances GABAergic neurotransmission, is one of the newest alternative treatments of Tourette syndrome (TS)."	3.74	Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome. ( Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN; Papageorgiou, C; Soldatos, CR, 2008)
"To develop a mouse model to mimic the behavioral and neurochemical changes of Tourette syndrome (TS) by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induction and to investigate the effects of fluoxetine and haloperidol on head twitch response (HTR) induced by DOI."	3.74	[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response]. ( Dai, XM; Lu, Y; Ma, HW; Yao, Y, 2007)
"A patient with Gilles de la Tourette syndrome treated with haloperidol, ingested once daily after awakening from sleep, exhibited an irregular sleep-wake pattern with a free-running component of approximately 48 h."	3.71	Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin. ( Ayalon, L; Dagan, Y; Hermesh, H, 2002)
"The paper of Seignot in 1961 is the first clinical description of the use of haloperidol to treat the symptoms of Gilles de la Tourette syndrome (GTS)."	3.69	Seignot's paper on the treatment of Tourette's syndrome with haloperidol. Classic Text No. 31 ( Hartley, N; Rickards, H; Robertson, MM, 1997)
"Erythrocyte and plasma choline parameters were compared in children (n = 63), aged 6-18 years, suffering from Tourette Syndrome (TS), their parents (n = 57), their unaffected siblings (n = 38), and an adult control group (n = 57)."	3.68	Controlled study of erythrocyte choline in Tourette syndrome. ( Hanin, I; Kopp, U; Sallee, FR, 1992)
"Clomipramine hydrochloride, a tricyclic antidepressant that blocks serotonin and norepinephrine reuptake, is indicated in the treatment of Obsessive-Compulsive Disorder."	3.68	Tourette's syndrome and treatment with clomipramine hydrochloride. ( Donahoe, DH; Fortune, T; Llorena, R; Meador, M, 1991)
"A ten year old boy developed features of Tourette syndrome while taking haloperidol for behaviour problems."	3.68	A case of Tourette syndrome developing during haloperidol treatment. ( Karagianis, JL; Nagpurkar, R, 1990)
"The relationship between a medication course with haloperidol (Haldol) and family history for any type of tics was examined in a survey of 196 Tourette syndrome patients."	3.67	Treating Tourette syndrome with haloperidol: predictors of success. ( Konkol, RJ; Schwabe, MJ, 1989)
"A 23-year-old male with a history of severe Tourette syndrome refractory to treatment with oral haloperidol is reported."	3.67	Treatment of refractory Tourette syndrome with haloperidol decanoate. ( Clarke, DJ; Ford, R, 1988)
"A dominant major gene was supported by analyses of 50 large extended Tourette syndrome (TS) pedigrees and by a subset of families defined by proband's clinical response to the neuroleptic drug haloperidol."	3.67	Family data support a dominant major gene for Tourette syndrome. ( Caine, ED; Kruger, SD; Pauls, DL; Price, RA, 1988)
"From among 1377 patients with movement disorders, four patients had an unusual movement disorder characterised by paroxysmal bursts of involuntary, regular, repetitive, rhythmic, bilateral, coordinated, simultaneous, stereotypic myoclonus and vocalisations, often associated with tonic symptoms, interference with voluntary functioning, presence of hyperactivity, attention and learning disabilities, and resistance to treatment with haloperidol and other drugs."	3.67	Paroxysmal myoclonic dystonia with vocalisations: new entity or variant of preexisting syndromes? ( Feinberg, TE; Shapiro, AK; Shapiro, E, 1986)
"In a female patient with Gilles-de-la Tourette syndrome (GTS) the clinical improvement during drug therapy of haloperidol and clomipramine was proved with the help of a polygraphic method (simultaneous recording of different electrophysiological and vegetative parameters)."	3.67	[Polygraphic therapy control in Gilles de la Tourette syndrome--a case report]. ( Gorynia, I; Seidel, M, 1986)
"The development of school phobia has been reported in some patients with Tourette syndrome treated with haloperidol."	3.67	Tourette syndrome, pimozide, and school phobia: the neuroleptic separation anxiety syndrome. ( Linet, LS, 1985)
"A prospective clinical and biochemical study on the effects of treatment with haloperidol has been performed in seven patients with Tourette syndrome."	3.66	Dopaminergic dsyfunction in Tourette syndrome. ( Butler, IJ; Coyle, JT; Seifert, WE; Singer, HS; Tune, LE, 1982)
"Fifty patients with Tourette syndrome were evaluated; data included family history, clinical characteristics, response to haloperidol, and side effects during haloperidol therapy."	3.66	Gilles de la Tourette syndrome: clinical and family study of 50 cases. ( Caine, ED; Ebert, MH; Eldridge, R; Nee, LE; Polinsky, RJ, 1980)
"Three patients suffering from Gilles de la Tourette Syndrome were initially treated with haloperidol."	3.65	Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. ( Erickson, HM; Goggin, JE; Messiha, FS, 1977)
"Children with Tourette's syndrome (TS) have a poor treatment compliance due to side effects and inconvenient administration of oral drugs."	2.74	[Efficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children]. ( Gao, XM; Guo, XY; Jiao, FY; Kang, H; Zhang, YF, 2009)
"Haloperidol-associated treatment-limiting adverse events were experienced by 41% of the patients."	2.68	Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. ( Jackson, C; Nesbitt, L; Sallee, FR; Sethuraman, G; Sine, L, 1997)
" Clinically significant cardiac effects did not occur at a maximum dosage of 0."	2.66	Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. ( Fulop, G; Hubbard, M; Mandeli, J; Nordlie, J; Phillips, RA; Shapiro, AK; Shapiro, E, 1989)
"Pimozide was associated with significantly fewer complaints of lethargy."	2.64	A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. ( Moldofsky, H; Ross, MS, 1978)
"Tics are typically waxing and waning in frequency and intensity."	2.61	[Patients with tic disorders: widely known, yet underserved]. ( Musil, R; Schnell, JML; Weidinger, E, 2019)
"Tardive Tourette syndrome is an extrapyramidal symptom which appears after long-term neuroleptic use."	2.43	[Two cases of tardive Tourette syndrome]. ( Ohmori, T; Yamauchi, K, 2006)
"This article reviews the evidence published in the English language literature concerning the pharmacological treatment of tics in patients with Tourette Syndrome."	2.42	Pharmacological management of tics in patients with TS. ( Sandor, P, 2003)
"Two patients with akathisia developing only after neuroleptic dosage reduction or withdrawal are described."	2.39	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. ( Lang, AE, 1994)
"The increasing recognition of Tourette's syndrome is probably responsible for the broadening range of symptom severities seen in clinic patients."	2.39	Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996)
"Sydenham's chorea is a symptom of rheumatic fever and results from an autoimmune attack on the CNS."	2.39	Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. ( Moore, DP, 1996)
"Gilles de la Tourette's syndrome, a combination of multiple chronic tics and vocalizations, usually first occurring during childhood, is described in its history, symptomatology, genetics, etiology and therapy."	2.38	[Gilles-de-la-Tourette syndrome]. ( Dressler, D; Schauenburg, H, 1992)
"Tourette's syndrome is a chronic tic disorder in which motor and vocal tics begin in childhood, persist to adulthood, and occur predominantly in males, often in a familial setting."	2.37	Tourette's syndrome. Some new concepts. ( Butler, IJ, 1984)
"Tourette syndrome has recently been brought to public attention through popular media."	2.37	Tourette syndrome: a review and educational implications. ( Bauer, AM; Shea, TM, 1984)
"Treatment with haloperidol is useful for 80% to 85% of patients but associated with troublesome side effects in one-half of those treated."	2.36	Tics in childhood. ( Golden, GS, 1983)
"Tourette's syndrome, or Gilles de la Tourette's disease, is a disorder characterized by involuntary tic-like muscular movements, compulsive behaviour and involuntary vocalization of sounds, words or profanities."	2.36	Tourette's syndrome: a treatable tic. ( Murray, TJ, 1978)
"To observe the effect of salidroside on tic behavior and in vivo dopamine DA) and serotonin (5-HT) levels in Tourette syndrome (TS) model rats."	1.43	[Effects of Salidroside on Tic Behavior of Tourette Syndrome Model Rats]. ( Ji, Y; Ren, LM; Wang, Z; Xie, H; Yang, WH; Yin, J, 2016)
"Nicotine did not induce catalepsy on its own."	1.39	Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome. ( Boye, SM, 2013)
" Initially, we established a dose-response relationship for the acute and chronic haloperidol and DOI-induced HTR."	1.33	Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. ( Hayslett, RL; Tizabi, Y, 2005)
"We present the anesthetic management for cesarean delivery of a 21-year-old pregnant woman with Tourette's syndrome."	1.33	Anesthetic management for cesarean delivery in a woman with Gilles de la Tourette's syndrome. ( Kocamanoglu, S; Sener, EB; Tur, A; Ustun, E, 2006)
"Tourette syndrome is defined and characterized mainly by the presence of motor and phonic tics."	1.32	Effects of medications on regulation of body temperature of patients with Tourette syndrome. ( Kessler, AR, 2004)
"The treatment of Tourette's syndrome (TS) is often unsatisfactory."	1.30	Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. ( Dursun, SM; Reveley, MA, 1997)
"A careful history suggested that Tourette's syndrome might be responsible for the patients' symptoms."	1.30	Tourette's syndrome mimicking asthma. ( Hogan, MB; Wilson, NW, 1999)
"Clinical assessment of a child with Tourette's syndrome (TS) includes a careful review of motor and phonic tics."	1.29	Tourette's syndrome, Part II: Contemporary approaches to assessment and treatment. ( Hardin, MT; Ort, SI; Scahill, L, 1993)
"Of 51 consecutive referrals to a Tourette's disorder clinic, 48 met DSM-III-R criteria for Tourette's disorder."	1.29	Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. ( Barickman, J; Daniel, W; Friedhoff, AJ; Muñoz, DM; Silva, RR, 1996)
"Two patients suffering from Tourette's Syndrome who had developed episodes of continual motor tics that lasted from minutes to hours, were non-suppressible and intruded into normal functioning, were treated with an increase in the dose of haloperidol, in one case with the addition of clonazepam."	1.29	Tics status. ( Chee, KY; Sachdev, P; Wilson, A, 1996)
"Gilles de la Tourette syndrome is characterized by (a) onset usually in childhood and adolescence between 2 and 15 years of age, (b) violent facial tics and coprolalia, (c) increased excitability and apathy, (d) progressive increase in the intensity of symptoms, and (e) a chronic course."	1.29	Gilles de la Tourette syndrome in Papua New Guinea. ( Johnson, FY, 1995)
"Two cases of Gilles de la Tourette syndrome from India are presented."	1.28	Gilles de la Tourette syndrome in India: two cases. ( Eapen, V; Srinath, S, 1992)
"Nicotine alone did not produce catalepsy."	1.28	Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. ( Emerich, DF; McConville, BJ; Norman, AB; Sanberg, PR; Zanol, MD, 1991)
"2."	1.28	Differential modulation of mouse brain biogenic amines by haloperidol and pimozide: implications in Tourette's syndrome. ( Messiha, FS, 1990)
"Nicotine was found to markedly potentiate haloperidol-induced hypokinesia in rats."	1.28	Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. ( Blythe, MM; Fogelson, HM; Klykylo, WM; Manderscheid, PZ; McConville, BJ; Norman, AB; Parker, KW; Sanberg, PR, 1989)
"A case of Gilles de la Tourette syndrome in a mildly mentally retarded adult female is described."	1.27	Gilles de la Tourette syndrome in mental handicap. ( Reid, AH, 1984)
"The estimated prevalence rate of Tourette's syndrome, 0."	1.27	Tourette's syndrome: update. ( Baird, PA; Connolly, JE; Freeman, RD, 1984)
"A total of 150 patients with Tourette's syndrome were treated by different neurotropic drugs."	1.27	[Treatment of Tourette syndrome]. ( Pushkov, VV, 1986)
"Tourette syndrome is a neuropsychiatric disorder of motor and vocal tics, with associated symptoms of obsessive-compulsive behaviors and attention deficit disorder with hyperactivity."	1.27	[The treatment of children with Gilles de la Tourette's syndrome]. ( Minderaa, RB, 1987)
"Twenty-six children with Tourette's syndrome (TS) and 24 with a temporal form of epilepsy were examined."	1.27	[Features of the temporal structure of the respiratory cycle in the Tourette syndrome as a possible reflection of intensified dopaminergic processes]. ( Kenunen, OG; Kharitonov, RA; Shchelkunov, EL; Voronov, IB; Zimin, AL, 1985)
"Gilles de la Tourette's syndrome (GTS) is a chronic neuropsychiatric disorder characterized by multiple involuntary motor and phonic tics associated with behavioural disturbances including obsessive-compulsive and aggressive behavior, depression and, rarely, psychosis."	1.27	Beneficial effects of imipramine on Tourette's syndrome. ( Bamford, CR; Sandyk, R, 1988)
"We report a patient in whom Tourette's syndrome (TS) and Type I schizophrenia coincided, and suggest, based on clinical features and pharmacological responses, that both conditions in this patient could have a common pathophysiological basis."	1.27	Gilles de la Tourette's syndrome associated with chronic schizophrenia. ( Bamford, CR; Sandyk, R, 1988)
"A patient with long-standing Tourette's syndrome had a dramatic exacerbation of symptoms following the rapid withdrawal of haloperidol."	1.27	Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal. ( Max, JE; Rasmussen, SA, 1986)
"Utilizing a case of Tourette's syndrome as an illustration, this paper seeks to refine the problem of causality in medical illness."	1.27	Remarks on the etiology of Gilles de la Tourette's syndrome. ( Meyer, BC; Rose, D, 1986)
"Over 86% of 58 patients with Gilles de la Tourette's syndrome achieved effective pharmacologic control of the symptoms for 3 months or longer."	1.27	Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. ( Mesulam, MM; Petersen, RC, 1987)
"Eight patients with Gilles de la Tourette's syndrome were examined."	1.27	[Accessory symptomatology and therapy of Gilles de la Tourette's disease]. ( Achkova, M; Terziev, D, 1987)
"Because patients with Tourette's syndrome have been reported to have increased red blood cell choline levels, choline levels were examined in relation to treatment response."	1.27	Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. ( Hanin, I; Kopp, U; Merikangas, JR; Merikangas, KR, 1985)
"Early signs of Tourette's syndrome may be difficult to distinguish from hyperactive and attention disordered symptoms, leading the clinician to consider, treatment with stimulants."	1.26	Stimulant medications precipitate Tourette's syndrome. ( Cohen, DJ; Detlor, J; Kremenitzer, MW; Lowe, TL; Shaywitz, BA, 1982)
"Gilles de la Tourette syndrome is frequently associated with symptoms characteristic of hyperactivity and often goes unrecognized for long periods of time."	1.26	Deleterious effects of drugs used for hyperactivity on patients with Gilles de la Tourette syndrome. ( Sleator, EK, 1980)
"Tourette's syndrome is a disorder of central nervous system functioning in which the most easily recognized symptoms of involuntary movements and vocalizations have been found to be responsive, in many cases, to pharmacotherapy with haloperidol."	1.26	Tourette's syndrome: an expanded view. ( O'Quinn, AN; Thompson, RJ, 1980)
"It was found that in patients with Tourette's syndrome PAG excretion with the urine was lowered, the degree of this lowering being independent of the patients' age, sex, and nourishment."	1.26	[Early diagnosis of the Tourette syndrome]. ( Khaĭlova, IM; Khokhlov, AP; Mel'nichuk, PV, 1980)
"A 7-year-old boy with multiple tic or Gilles de la Tourette's disease was treated with haloperidol."	1.26	Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. ( Holtzman, D; Mizrahi, EM; Tharp, B, 1980)
"Treatment with haloperidol produced a marked improvement in the symptoms, some of which are seldom reported."	1.26	Gilles de la Tourette's syndrome: case report. ( Shenken, LI, 1980)
"It is the drug of choice for Tourette's syndrome, and may be useful in nonpsychotic hyperactive or aggressive children to control acute episodes, or when the stimulants normally useful in hyperactive children are ineffective."	1.26	Haloperidol -- its use in children. ( Serrano, AC, 1981)
"This suggests that symptoms of Gilles de la Tourette syndrome which appear after withdrawal of chronic neuroleptic therapy may be due to transient hypersensitivity of dopamine receptor sites."	1.26	Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal. ( Singer, WD, 1981)
"Fifteen patients with Tourette's disorder developed school and work avoidance syndromes when treated with low doses (mean 2."	1.26	School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. ( Cohen, DJ; Detlor, J; Mikkelsen, EJ, 1981)
"Nine of them had generalized tic (Gilles de la Tourette's disease), and 43 had local forms."	1.26	[Pathogenesis and treatment of tic-type hyperkinesis in children]. ( Blagosklonov, AV; Bondarenko, ES; Lebedev, VN; Malyshev, IuI, 1981)
"Treatment with haloperidol is effective but associated with a high incidence of side effects."	1.26	Tics and tremors. ( Golden, GS; Hood, OJ, 1982)
"This diverse group of Tourette's syndrome (TS) patients supplied by mail detailed medical, symptom, developmental, family, and personal history information."	1.26	The epidemiology of Tourette's syndrome: a pilot study. ( Carbonari, CM; Cohen, DJ; Jagger, J; John, K; Kidd, KK; Prusoff, BA, 1982)
"Haloperidol (10(-5)M) was also shown to be a strong non-competitive inhibitor of 14C-DA uptake by platelets."	1.26	Platelet dopamine uptake in Huntington's chorea and Gilles de la Tourette's syndrome: effect of haloperidol. ( Barbeau, A; Butterworth, RF; Gonce, M, 1977)
"Treatment with haloperidol produces a good or excellent response in three quarters of the patients."	1.26	Tourette syndrome. The pediatric perspective. ( Golden, GS, 1977)
"A case of Gilles de la Tourette's syndrome with alcoholism and migraine is described."	1.26	A case of Gilles de la Tourette's syndrome accompanied with alcoholism. ( Iwase, N; Katoh, N; Takahashi, S; Tani, N; Yamane, H, 1977)
"Gilles de la Tourette's syndrome was independently ascertained in two male cousins once removed."	1.26	Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. ( Cohen, NL; Friedhoff, AJ; Pollack, MA, 1977)
"Treatment with haloperidol suggested as a most effective method of symptomatic treatment."	1.26	Gilles de la Tourett's disease, a single case study: a discussion on aetiology and treatment. ( Izadi, C; Naraghi, MM, 1978)
"Five cases of Gilles de la Tourette's syndrome occurring in the Chinese are described."	1.26	Gilles de la Tourette's syndrome: report of five cases in the Chinese. ( Leung, L; Lieh-Mak, F; Luk, SL, 1979)
"Six cases of Gilles de la Tourette's syndrome are discussed in the light of conflicting views on the aetiology of the condition."	1.26	Six cases of Gilles de la Tourette's syndrome. ( Fernando, SJ, 1976)
"This longitudinal, blind study of Gilles de la Tourette's disease in a 44 year old male patient who was nonresponsive to Haloperidol therapy indicates that dopamine excretion is related to clinical response."	1.26	A study of endogenous dopamine metabolism in Gilles de la Tourette's disease. ( Knopp, W; Messiha, FS, 1976)
"In five patients with Tourette's syndrome, we found in the CSF an elevated probenecid-induced accumulation of HVA, the major metabolite of dopamine."	1.26	Gilles de la Tourette's syndrome: biochemical approaches. ( Bowers, MB; Jutkowitz, R; Rosenbaum, D; Van Woert, MH, 1976)
"Two cases of Gilles de la Tourette's syndrome occurring in Sri Lanka are reported."	1.25	Two cases of Gilles de la Tourette's syndrome treated with haloperidol. ( Perera, HV, 1975)

Research

Studies (300)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

"Number of Patients With Improved or Minimally Improved in Clinical Global Impression-Improvement (CGI) Scale"

Timeframe	Studies, this research(%)	All Research%
pre-1990	221 (73.67)	18.7374
1990's	49 (16.33)	18.2507
2000's	16 (5.33)	29.6817
2010's	12 (4.00)	24.3611
2020's	2 (0.67)	2.80

Authors	Studies
Schnell, JML	1
Weidinger, E	1
Musil, R	1
Zhao, L	2
Cheng, N	1
Sun, B	1
Wang, S	1
Li, A	2
Wang, Z	2
Wang, Y	1
Qi, F	1
Mosher, LJ	1
Godar, SC	1
Nelson, M	1
Fowler, SC	1
Pinna, G	1
Bortolato, M	2
Nespoli, E	1
Rizzo, F	1
Boeckers, T	1
Schulze, U	1
Hengerer, B	1
Cadeddu, R	1
Bäckström, T	1
Floris, G	1
Nordkild, P	1
Segerdahl, M	1
Zhang, F	1
Zheng, W	1
Li, XB	1
Xiang, YQ	1
Zhong, BL	1
Chiu, HF	1
Ungvari, GS	1
Ng, CH	1
Lok, GK	1
Xiang, YT	1
Jiao, F	1
Zhang, X	2
Wang, J	1
Xie, H	1
Ji, Y	1
Yin, J	1
Yang, WH	1
Ren, LM	1
Bastiampillai, T	1
Dhillon, R	1
Mohindra, R	1
Pringsheim, T	1
Marras, C	1
Kang, H	1
Zhang, YF	1
Jiao, FY	1
Guo, XY	1
Gao, XM	1
Li, AY	1
Cong, S	1
Lu, H	1
Li, JJ	1
Taylor, JL	1
Rajbhandari, AK	1
Berridge, KC	1
Aldridge, JW	1
Kovacs, N	1
Herold, R	1
Janszky, J	1
Komoly, S	1
Nagy, F	1
Braña-Berríos, M	1
Lam, K	1
Coffey, B	1
Nakamae, T	1
Boye, SM	1
Ayalon, L	1
Hermesh, H	1
Dagan, Y	1
Majumdar, A	1
Appleton, RE	1
Sandor, P	2
SEIGNOT, JN	1
CHALLAS, G	2
BRAUER, W	1
CHAPEL, JL	3
BROWN, N	1
JENKINS, RL	3
Kano, Y	1
Kessler, AR	1
Hayslett, RL	1
Tizabi, Y	1
Sener, EB	1
Kocamanoglu, S	1
Ustun, E	1
Tur, A	1
Yamauchi, K	1
Ohmori, T	1
Oulis, P	1
Karapoulios, E	1
Masdrakis, VG	1
Kouzoupis, AV	1
Karakatsanis, NA	1
Papageorgiou, C	1
Papadimitriou, GN	1
Soldatos, CR	1
Yao, Y	1
Ma, HW	1
Lu, Y	1
Dai, XM	1
Butler, IJ	3
Yassa, R	1
Ananth, J	1
Kharitonov, RA	2
Pushkov, VV	2
Lowe, TL	1
Cohen, DJ	10
Detlor, J	2
Kremenitzer, MW	1
Shaywitz, BA	1
Klawans, HL	2
Nausieda, PA	1
Goetz, CC	1
Tanner, CM	2
Weiner, WJ	1
Fog, R	1
Pakkenberg, H	1
Regeur, L	1
Pakkenberg, B	1
Realmuto, GM	1
Main, B	1
Tolosa Sarró, E	1
Bayés Rusiñol, A	1
Muñoz Yunta, JA	1
Shapiro, AK	20
Shapiro, E	18
Eisenkraft, GJ	2
Comings, DE	2
Comings, BG	2
Golden, GS	6
Gillies, DR	1
Forsythe, WI	1
van Woert, MH	2
Rosenbaum, D	2
Enna, SJ	1
Singer, HS	4
Tune, LE	3
Seifert, WE	1
Coyle, JT	4
Meltzer, HY	1
Leckman, JF	7
Bauer, AM	1
Shea, TM	1
Chen, HB	1
Lu Fei, HQ	1
Reid, AH	1
Lang, AE	2
Marsden, CD	2
Ashby, HB	1
Subrahmanya, B	1
Channabasavanna, SM	1
Pradhan, N	1
Borison, RL	3
Ang, L	2
Hamilton, WJ	1
Diamond, BI	2
Davis, JM	3
Sutula, T	1
Hobbs, WR	1
Min, SK	2
Bruun, RD	8
Caine, ED	12
Ludlow, CL	2
Polinsky, RJ	5
Ebert, MH	4
Wang, SY	1
Soong, WT	1
Freeman, RD	1
Connolly, JE	1
Baird, PA	1
Ferrari, M	1
Matthews, WS	1
Barabas, G	1
Fennig, S	1
Bauer, A	1
Kronnenberg, Y	1
Paolucci, S	1
Buttinelli, C	1
Fiume, S	1
Ciani, S	1
Lenzi, GL	1
Lakke, JP	2
Sverd, J	1
Kupietz, S	1
Chang, S	1
Dysken, M	1
Comaty, JE	1
Nee, LE	2
Eldridge, R	2
Barbeau, A	3
Sleator, EK	1
Mendelson, WB	2
Goyer, P	1
Ebert, M	1
Gillin, JC	1
O'Quinn, AN	1
Thompson, RJ	1
Mel'nichuk, PV	1
Khokhlov, AP	1
Khaĭlova, IM	1
Mizrahi, EM	1
Holtzman, D	1
Tharp, B	1
Shenken, LI	1
Menawat, AS	1
Singh, HB	1
Panwar, RB	1
Kochar, DK	1
Saksena, HC	1
Serrano, AC	1
Surwillo, WW	2
Rabins, P	1
Bachman, DS	1
Singer, WD	1
Mikkelsen, EJ	1
Bondarenko, ES	2
Malyshev, IuI	1
Blagosklonov, AV	1
Lebedev, VN	1
Daniel, AE	1
Hood, OJ	1
Dupont, E	1
Nørgaard, B	1
Jagger, J	1
Prusoff, BA	1
Kidd, KK	3
Carbonari, CM	1
John, K	1
Mueller, J	1
Aminoff, MJ	1
Domino, EF	1
Piggott, L	1
Demetriou, S	1
Culbert, J	1
Friedhoff, AJ	4
Zaczek, R	1
Reyes, MG	1
Borison, R	1
Nomura, Y	1
Segawa, M	1
Mak, FL	1
Chung, SY	1
Lee, P	1
Chen, S	1
Asam, U	2
Goetz, CG	1
Bogomolny, A	1
Erenberg, G	4
Rothner, AD	3
McDougle, CJ	1
Goodman, WK	1
Price, LH	1
Jaffe, E	1
Trémeau, F	1
Sharif, Z	1
Reider, R	1
Takano, K	1
Ishiguro, T	1
Budman, CL	1
Sherling, M	1
Sallee, FR	4
Sethuraman, G	3
Rock, CM	1
Toren, P	1
Toren, A	1
Weizman, A	1
Mozes, T	1
Eldar, S	1
Magor, A	1
Mandel, M	1
Rechavi, G	1
Many, A	1
Mester, R	1
Silver, AA	2
Sanberg, PR	7
Silva, RR	2
Alpert, M	1
Scahill, L	1
Ort, SI	1
Hardin, MT	2
Escobar, R	1
Bernardo, M	1
Buckingham, D	1
Gaffney, G	1
Muñoz, DM	1
Daniel, W	1
Barickman, J	1
Tarsy, D	1
Miyawaki, E	1
Rickards, H	2
Bharucha, KJ	1
Sethi, KD	1
Peterson, BS	1
Sachdev, P	1
Chee, KY	1
Wilson, A	1
Dougherty, D	1
Vrindavanam, N	1
Erdmann, R	1
Rosenquist, PB	1
Bodfish, JW	1
Thompson, R	1
Dursun, SM	1
Reveley, MA	1
Iur'eva, EA	1
Zykov, VP	1
Alekseeva, NV	1
Nesbitt, L	1
Jackson, C	1
Sine, L	1
Murray, JB	1
Johnson, FY	1
Moore, DP	1
Arzimanoglou, AA	1
Rupp, SN	1
Hogan, MB	1
Wilson, NW	1
Rojas, VM	1
Davies, RK	1
Van Ameringen, M	1
Mancini, C	1
Oakman, JM	1
Farvolden, P	1
Coffey, BJ	1
Biederman, J	1
Geller, DA	1
Spencer, T	1
Park, KS	1
Shapiro, SJ	1
Garfield, SB	1
Hartley, N	1
Robertson, MM	1
Shytle, RD	1
Philipp, MK	1
Wilkinson, BJ	1
McConville, B	1
Pary, RJ	1
Heath, A	1
Rose, MS	1
Moldofsky, H	5
Butterworth, RF	1
Gonce, M	1
Lake, CR	1
Ziegler, MG	1
Murphy, DL	1
Yamane, H	1
Katoh, N	1
Tani, N	1
Iwase, N	1
Takahashi, S	1
Pollack, MA	1
Cohen, NL	1
Erickson, HM	2
Goggin, JE	2
Messiha, FS	6
Margolin, DI	1
Brown, GL	1
Frank, SM	1
Fras, I	1
Shafii, M	1
Barrett, CL	1
Izadi, C	1
Naraghi, MM	1
Loriaux, DL	1
Crosley, CJ	1
Lieh-Mak, F	1
Luk, SL	1
Leung, L	1
Izmeth, A	1
Badalian, LO	1
Skvortsov, IA	1
Kamennykh, LN	1
Dadali, EL	1
Temin, PA	1
Tomaszewski, J	1
Seredyński, R	1
Gonge, M	1
Ross, MS	1
Murray, TJ	1
Feinberg, M	1
Carroll, BJ	1
Ban, TA	1
Pecknold, JC	1
Goldstone, S	1
Lhamon, WT	1
Barker, P	1
Milman, DH	1
Araneta, E	1
Magen, J	1
Musci, MN	1
Singer, P	1
Vann, CR	1
Perera, HV	1
Träger, SE	1
Fernando, SJ	1
Sweet, R	1
Wayne, H	3
Solomon, GE	2
Knopp, W	3
Boshes, LD	1
Jutkowitz, R	1
Bowers, MB	1
Lal, S	1
Allen, J	1
Etienne, P	1
Sourkes, TL	1
Humphreys, P	1
Verma, KC	1
Magotra, ML	1
Kopp, U	2
Hanin, I	2
Schauenburg, H	1
Dressler, D	1
Arevalo, E	1
Licamele, WL	1
Bronheim, S	1
Sonnenschein, K	1
Riddle, MA	2
Eapen, V	1
Srinath, S	1
Rickards, EH	1
McConville, BJ	5
Fogelson, MH	2
King, J	1
Cirino, P	1
Parker, KW	4
Norman, AB	5
Donahoe, DH	1
Meador, M	1
Fortune, T	1
Llorena, R	1
Klykylo, WM	2
Manderscheid, PZ	3
Emerich, DF	1
Zanol, MD	1
Musisi, S	1
Lang, A	1
Karagianis, JL	1
Nagpurkar, R	1
Littlejohns, CS	1
Clarke, DJ	2
Corbett, JA	1
Sandyk, R	3
Fulop, G	2
Hubbard, M	1
Mandeli, J	1
Nordlie, J	1
Phillips, RA	2
Fogelson, HM	2
Blythe, MM	1
Smith, SJ	1
Lees, AJ	1
Schwabe, MJ	1
Konkol, RJ	1
Price, RA	3
Pauls, DL	3
McDaniel, KD	1
Minderaa, RB	1
Aksent'ev, SB	1
Borisova, NP	1
Levinskiĭ, MV	1
Kryzhanovskiĭ, GN	1
Perry, R	1
Nobler, MS	1
Campbell, M	1
Alessi, NE	1
Walden, M	1
Hsieh, PS	1
Shchelkunov, EL	1
Kenunen, OG	1
Voronov, IB	1
Zimin, AL	1
McBride, MC	1
Chiverton, P	1
Bamford, KA	1
Rediess, S	1
Shiao, J	1
Bamford, CR	2
Ford, R	1
Kruger, SD	1
Flynn, SP	1
Jacobs, I	1
Guinter, W	1
Max, JE	1
Rasmussen, SA	1
Feinberg, TE	1
Meyer, BC	1
Rose, D	1
Seidel, M	1
Gorynia, I	1
Towbin, KE	1
Lee, H	1
Widlöcher, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT00004325]		200 participants	Observational	1988-12-31	Completed
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
Transdermal Nicotine in Female Patients at High Risk for PONV[NCT00775749]		0 participants (Actual)	Interventional	2009-04-30	Withdrawn (stopped due to The study is not feasible with the number of subjects needed to complete it.)
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling[NCT03300167]		0 participants (Actual)	Interventional	2017-11-30	Withdrawn (stopped due to Delivery of equipment. PI not had any further interaction with the company so closed study.)
Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder[NCT00231985]	Phase 2	122 participants (Actual)	Interventional	2005-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

"Number of Patients With Much Improved or Very Much Improved on Clinical Global Impression-Improvement (CGI) Scale"

Intervention	participants (Number)
Active	2
Sham	8

Motor Cortex Excitability Normalization-Left Motor Threshold

Intervention	participants (Number)
Active	1
Sham	0

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

Motor Cortex Excitability Normalization-Right Motor Threshold

Intervention	µV (Mean)
Active	56.5
Sham	63.8

Yale Global Tic Severity Scale (Y-GTSS)

Intervention	µV (Mean)
Active	56
Sham	59.8

Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks

Reviews

Trials

Other Studies

242 other studies available for haloperidol and Chronic Motor and Vocal Tic Disorder

Article	Year
[Patients with tic disorders: widely known, yet underserved]. Fortschritte der Neurologie-Psychiatrie, 2019, Volume: 87, Issue:10 Topics: Europe; Haloperidol; Humans; Off-Label Use; Tic Disorders; Tics; Tourette Syndrome	2019
Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis. Human psychopharmacology, 2016, Volume: 31, Issue:1 Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child; Haloperidol; Humans;	2016
Pimozide for tics in Tourette's syndrome. The Cochrane database of systematic reviews, 2009, Apr-15, Issue:2 Topics: Anti-Dyskinesia Agents; Haloperidol; Humans; Pimozide; Randomized Controlled Trials as Topic; Risper	2009
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2011, Volume: 113, Issue:10 Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disru	2011
Pharmacological management of tics in patients with TS. Journal of psychosomatic research, 2003, Volume: 55, Issue:1 Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Clonidine; Dopamine Antagonists; Haloperidol; Humans;	2003
[Chronic tic disorders--chronic mortor or vocal tic disorders and de la Tourette's syndrome]. Ryoikibetsu shokogun shirizu, 2003, Issue:40 Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sy	2003
[Two cases of tardive Tourette syndrome]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Alcoholism; Amantadine; Antipsychotic Agents; Cholinergic Antagonist	2006
Tourette's syndrome. Some new concepts. Neurologic clinics, 1984, Volume: 2, Issue:3 Topics: Antipsychotic Agents; Female; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male	1984
Lithium carbonate in the treatment of movement disorders. A critical review. International pharmacopsychiatry, 1980, Volume: 15, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Deanol; Dopamine; Double-Blind Method;	1980
[Gilles de la Tourette's syndrome: diagnosis, pathogenesis and treatment]. Medicina clinica, 1983, Apr-16, Volume: 80, Issue:13 Topics: Adolescent; Adult; Child; Child, Preschool; Diagnosis, Differential; Female; Haloperidol; Humans; Ma	1983
Treatment of multiple tics and the Tourette syndrome. Developmental medicine and child neurology, 1984, Volume: 26, Issue:6 Topics: Adolescent; Antipsychotic Agents; Benztropine; Child; Child, Preschool; Clonidine; Haloperidol; Huma	1984
Dopamine autoreceptor stimulation: clinical significance. Pharmacology, biochemistry, and behavior, 1982, Volume: 17 Suppl 1 Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson	1982
Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research. Psychiatric developments, 1983,Autumn, Volume: 1, Issue:3 Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Compulsive	1983
Tics in childhood. Pediatric annals, 1983, Volume: 12, Issue:11 Topics: Child; Chronic Disease; Female; Haloperidol; Humans; Male; Prognosis; Tic Disorders; Tourette Syndro	1983
Tourette syndrome: a review and educational implications. Journal of autism and developmental disorders, 1984, Volume: 14, Issue:1 Topics: Adolescent; Child; Child, Preschool; Clonidine; Education, Special; Female; Haloperidol; Humans; Mal	1984
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists	1994
Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Bipolar Disorder; Dose-Response Relationship, Drug; Drug	1994
Tics and fits. The current status of Gilles de la Tourette syndrome and its relationship with epilepsy. Seizure, 1995, Volume: 4, Issue:4 Topics: Antipsychotic Agents; Diagnosis, Differential; Epilepsies, Partial; Haloperidol; Humans; Obsessive-C	1995
Tardive tourettism after exposure to neuroleptic therapy. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:6 Topics: Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male	1995
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 9 Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas	1996
[Nicotine in neuropsychiatric movement disorders]. Fortschritte der Neurologie-Psychiatrie, 1996, Volume: 64, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Brain; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Nicotin	1996
Psychophysiological aspects of Tourette's syndrome. The Journal of psychology, 1997, Volume: 131, Issue:6 Topics: Adolescent; Adult; Brain; Child; Child, Preschool; Dominance, Cerebral; Female; Haloperidol; Humans;	1997
Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:9 Topics: Adult; Autoimmune Diseases; Chorea; Comorbidity; Haloperidol; Humans; Mental Disorders; Obsessive-Co	1996
Gilles de la Tourette syndrome. Journal of neurology, 1998, Volume: 245, Issue:12 Topics: Child; Cholinergic Antagonists; Haloperidol; Humans; Tic Disorders; Tourette Syndrome	1998
The course of Tourette's disorder: a literature review. Harvard review of psychiatry, 2000, Volume: 8, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Child; Comorbidity; Disease Progression; Europe; Haloperido	2000
Psychiatric drug treatment in children. The Journal of the Maine Medical Association, 1979, Volume: 70, Issue:5 Topics: Adolescent; Amphetamines; Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child;	1979
[Gilles de la Tourette's disease]. L'union medicale du Canada, 1977, Volume: 106, Issue:4 Topics: Antiparkinson Agents; Brain; Diagnosis, Differential; Diagnostic Errors; gamma-Aminobutyric Acid; Ha	1977
Tourette's syndrome: a treatable tic. Canadian Medical Association journal, 1978, Jun-10, Volume: 118, Issue:11 Topics: Butyrophenones; Compulsive Behavior; Female; Haloperidol; Humans; Male; Muscles; Remission, Spontane	1978
Haloperidol in the therapy of severe behavior disorders. Current psychiatric therapies, 1976, Volume: 16 Topics: Benperidol; Bipolar Disorder; Child Behavior; Dementia; Droperidol; Haloperidol; Humans; Neurocognit	1976
[Gilles-de-la-Tourette syndrome]. Der Nervenarzt, 1992, Volume: 63, Issue:8 Topics: Combined Modality Therapy; Haloperidol; Humans; Neuropsychological Tests; Pimozide; Psychotherapy; S	1992
Pharmacotherapy of Tourette's syndrome and associated disorders. The Psychiatric clinics of North America, 1992, Volume: 15, Issue:1 Topics: Attention Deficit Disorder with Hyperactivity; Clonidine; Female; Haloperidol; Humans; Male; Mental	1992
Gilles de la Tourette's syndrome. A review of clinical and research studies and consideration of future directions for investigation. Archives of neurology, 1985, Volume: 42, Issue:4 Topics: Adolescent; Adult; Animals; Behavior Therapy; Brain; Child; Child, Preschool; Clinical Trials as Top	1985
Gilles de la Tourette's disease--a review. The American journal of psychiatry, 1974, Volume: 131, Issue:9 Topics: Adolescent; Age Factors; Child; Child, Preschool; Corpus Striatum; Diagnosis, Differential; Female;	1974

Article	Year
Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2016, Volume: 20, Issue:1 Topics: Antipsychotic Agents; Asian People; Blood Pressure; Child; Child, Preschool; Clonidine; Female; Halo	2016
[Efficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2009, Volume: 11, Issue:7 Topics: Administration, Cutaneous; Adolescent; Child; Child, Preschool; Clonidine; Female; Haloperidol; Huma	2009
Clinical observation on treatment of Tourette syndrome by integrative medicine. Chinese journal of integrative medicine, 2009, Volume: 15, Issue:4 Topics: Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th	2009
Lithium carbonate in the treatment of movement disorders. A critical review. International pharmacopsychiatry, 1980, Volume: 15, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Deanol; Dopamine; Double-Blind Method;	1980
Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Archives of general psychiatry, 1983, Volume: 40, Issue:11 Topics: Adult; Antipsychotic Agents; Attitude to Health; Clinical Trials as Topic; Clonidine; Drug Therapy,	1983
Treatment of Gilles de la Tourette syndrome with pimozide. The American journal of psychiatry, 1983, Volume: 140, Issue:9 Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged;	1983
Treatment approaches in Gilles de la Tourette syndrome. Brain research bulletin, 1983, Volume: 11, Issue:2 Topics: Amantadine; Benztropine; Clonidine; Fluphenazine; Haloperidol; Humans; Lithium; Tourette Syndrome; T	1983
New pharmacological approaches in the treatment of Tourette syndrome. Advances in neurology, 1982, Volume: 35 Topics: Adolescent; Adult; Amantadine; Benztropine; Child; Clinical Trials as Topic; Clonidine; Female; Flup	1982
Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta psychiatrica Scandinavica, 1994, Volume: 90, Issue:1 Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Calcium Channels; Child; Cognition; Dose-	1994
Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biological psychiatry, 1996, Nov-15, Volume: 40, Issue:10 Topics: Adolescent; Anti-Dyskinesia Agents; Basal Ganglia Diseases; Child; Cross-Over Studies; Double-Blind	1996
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. The American journal of psychiatry, 1997, Volume: 154, Issue:8 Topics: Adolescent; Basal Ganglia Diseases; Child; Cross-Over Studies; Double-Blind Method; Drug Administrat	1997
The potential role of haloperidol in the treatment of trichotillomania. Journal of affective disorders, 1999, Volume: 56, Issue:2-3 Topics: Adult; Anti-Dyskinesia Agents; Female; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive	1999
Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:9 Topics: Administration, Cutaneous; Antipsychotic Agents; Cotinine; Double-Blind Method; Drug Administration	2001
Comparison of pimozide with haloperidol in Gilles de la Tourette syndrome. Lancet (London, England), 1977, Jan-08, Volume: 1, Issue:8002 Topics: Clinical Trials as Topic; Drug Evaluation; Haloperidol; Humans; Male; Pimozide; Tourette Syndrome	1977
A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. The American journal of psychiatry, 1978, Volume: 135, Issue:5 Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Ha	1978
Effects of dopamine agonists and antagonists in Tourette's disease. Archives of general psychiatry, 1979, Volume: 36, Issue:9 Topics: Adolescent; Adult; Amphetamine; Apomorphine; Child; Clinical Trials as Topic; Dextroamphetamine; Dop	1979
The behavior therapies: therapeutic breakthrough or latest fad? The American journal of psychiatry, 1976, Volume: 133, Issue:2 Topics: Behavior Therapy; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; History, 20th Cent	1976
A followup of eighty patients with Tourette's syndrome. Psychopharmacology bulletin, 1976, Volume: 12, Issue:2 Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Female; Follow-Up Studies; Haloperidol; Hu	1976
Haloperidol in psychiatry. The Medical letter on drugs and therapeutics, 1975, Jan-31, Volume: 17, Issue:3 Topics: Anxiety Disorders; Basal Ganglia Diseases; Clinical Trials as Topic; Dopamine Antagonists; Fluphenaz	1975
The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biological psychiatry, 1992, Apr-15, Volume: 31, Issue:8 Topics: Adolescent; Adult; Chewing Gum; Child; Drug Synergism; Drug Therapy, Combination; Female; Haloperido	1992
Tourette syndrome: a follow-up study. Journal of clinical psychopharmacology, 1990, Volume: 10, Issue:3 Topics: Adolescent; Adult; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Haloperidol; Humans; Long-Te	1990
Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of general psychiatry, 1989, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Double-Blind Method; Electrocardiography;	1989
Gilles de la Tourette's syndrome. A review of clinical and research studies and consideration of future directions for investigation. Archives of neurology, 1985, Volume: 42, Issue:4 Topics: Adolescent; Adult; Animals; Behavior Therapy; Brain; Child; Child, Preschool; Clinical Trials as Top	1985
ECG changes during haloperidol and pimozide treatment of Tourette's disorder. The American journal of psychiatry, 1987, Volume: 144, Issue:5 Topics: Adult; Clinical Trials as Topic; Electrocardiography; Female; Haloperidol; Heart; Heart Rate; Humans	1987
An objective evaluation of haloperidol in Gilles de la Tourette's syndrome. Diseases of the nervous system, 1969, Volume: 30, Issue:5 Topics: Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Placebos; Substance	1969
Controlled trial of the treatment of 36 stutterers. The British journal of psychiatry : the journal of mental science, 1971, Volume: 119, Issue:553 Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Intelligence Tests; Male;	1971
A psychophysiological study of multiple tics. Archives of general psychiatry, 1971, Volume: 25, Issue:1 Topics: Adult; Automatism; Central Nervous System; Child Development; Child, Preschool; Electroencephalograp	1971